aibioSana Biotechnology prices $75.0 million offering at $3.35 a share
Tickers SANA
Sana sold 20,895,522 shares at $3.35 plus pre-funded warrants for 1,492,537 more, with about $70.0 million in estimated net proceeds. It reported about $90.1 million in cash at July 31, 2025 and estimates $40.0 million to $45.0 million in facility impairments.
Key facts
- Company
- Sana Biotechnology, Inc. (NASDAQ: SANA)
- News type
- Financings
- Primary source
- Sana Biotechnology, Inc. 424B5 (2025-08-06)
Sana Biotechnology, Inc. (Nasdaq: SANA) priced an underwritten public offering on August 6, 2025 of 20,895,522 shares of common stock at $3.35 per share. Some investors took pre-funded warrants instead, for 1,492,537 shares at $3.3499 each, which is the share price less the $0.0001 exercise price. The Seattle company expects gross proceeds of about $75.0 million before underwriting discounts and offering expenses. The underwriters also hold a 30-day option to buy up to 3,358,208 more shares.
The company estimates net proceeds of about $70.0 million, or $80.6 million if the option is exercised in full. The last reported sale price was $4.26 on August 5, 2025, so the deal priced below the prior day's level. The offering was expected to close on or about August 8, 2025, subject to customary closing conditions.
Banks and counsel
Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC and BofA Securities, Inc. act as representatives of the underwriters. The company's pricing release also names TD Cowen as a joint book-running manager. Wilson Sonsini Goodrich & Rosati, P.C. passes on the validity of the securities for Sana, and Cooley LLP represents the underwriters.
Cash, facilities and an earlier at-the-market program
Sana had about $90.1 million in cash, cash equivalents and marketable securities as of July 31, 2025. The prospectus describes that figure as preliminary and unaudited.
Because of changes to its business plans, Sana intends to pursue subleases for its Bothell and Seattle, Washington facilities. It has also suspended further build-out of internal manufacturing capacity at Bothell, citing greater availability of outside manufacturing capacity. The company estimates non-cash impairment losses of $40.0 million to $45.0 million tied to those facilities in the month ended May 31, 2025.
Between April 1, 2025 and the prospectus date, Sana sold 7,441,376 shares under an at-the-market sales agreement with TD Securities (USA) LLC, dated May 8, 2025, for net proceeds of $29.1 million. That means the company has been raising money from the market on a rolling basis in addition to this deal.
The prospectus says Sana believes the net proceeds, together with current cash and marketable securities, will fund planned operations for at least one year from the date of the prospectus. It also says the company may still include going concern language in future reports describing substantial doubt about its ability to continue.
The clinical case
Sana's lead work is in engineered islet cells for type 1 diabetes, and the offering is aimed at both clinical and preclinical programs. In June 2025 the company reported six-month results from its UP421 IST study, run with collaborators at Uppsala University Hospital. The company says the study met all primary and secondary endpoints, that transplanted cells produced insulin and survived through six months, and that no safety issues were identified. A New England Journal of Medicine article published in August 2025 discusses the 12-week results. The company says it expects additional data, including longer-term follow-up, as the year progresses. Sana's March 2025 annual report says its twelve-week data come from one recipient, a 42-year-old who had lived with T1D for over 30 years and received a single transplant into a forearm muscle. Those results are the company's own description of a one-patient study that is still running.
The company says the proceeds, together with existing cash, will support preclinical work on SC451 and SG299, the more advanced SC291 and SC262 candidates, earlier-stage research, working capital and other corporate purposes. It may also use part of the money to in-license, acquire or invest in other businesses.
What the deal does and does not show
The offering was priced below the prior sale price and adds shares against a base of 225,463,072 shares outstanding as of March 31, 2025, according to the prospectus. The company also has an at-the-market program running alongside it. Its cash balance, its facility write-downs and its going concern caveat all point to a company that needs continued access to the market. The clinical data it cites are the company's own reading of a one-patient study that has not yet reported longer-term results.